Prosecution Insights
Prosecution Insights
14 pending office actions • 12 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 8 (57%) |
| §102 only | 2 (14%) |
| Double-patenting + other | 1 (7%) |
| No statute on record | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 45.8% | +50.0% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.4% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 36.4% | +70.1% |
| JUEDES, AMY E | 1 | 44.5% | +41.0% |
| HADDAD, MAHER M | 1 | 50.4% | +54.3% |
| NGUYEN, NGOC-ANH THI | 1 | 33.3% | +41.4% |
| VAN BUREN, LAUREN K | 1 | 38.9% | +57.3% |
| HERRMANN, JOSEPH S | 1 | 63.4% | +41.4% |
| SHOMER, ISAAC | 1 | 63.1% | +30.7% |
| SPICER, JENINE MARIE | 1 | 50.9% | +18.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18071705 | RNA FORMULATION FOR IMMUNOTHERAPY | SHOMER, ISAAC | 80d overdue |
| 18246533 | PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY | NGUYEN, NGOC-ANH THI | 60d overdue |
| 18268594 | Treatment Schedule for Cytokine Proteins | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 31d overdue |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 26d |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 29d |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 55d |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | HADDAD, MAHER M | 70d |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1641 | 2 |
| 1646 | 1 |
| 1644 | 1 |
| 1615 | 1 |
| 1638 | 1 |
| 3746 | 1 |
| 1612 | 1 |
| 3736 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268594 | Treatment Schedule for Cytokine Proteins | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §103 | Non-Final OA | 31d overdue | Pending | Jun 20, 2023 |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 1646 | Other | Non-Final OA | 26d | Pending | Jun 20, 2023 |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102 | Non-Final OA | 4d overdue | Pending | Jun 16, 2023 |
| 18038818 | ANTIBODY AND TAXANE COMBINATION THERAPY | JUEDES, AMY E | 1644 | DPOther | Final Rejection | 75d | Pending | May 25, 2023 |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | HADDAD, MAHER M | 1641 | §103 | Non-Final OA | 70d | Pending | Apr 14, 2023 |
| 18246533 | PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY | NGUYEN, NGOC-ANH THI | 1615 | §102 | Final Rejection | 60d overdue | Pending | Mar 24, 2023 |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 1638 | §103 | Non-Final OA | 29d | Pending | Mar 10, 2023 |
| 18180073 | SYSTEMS AND METHODS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS USING PERISTALTIC PUMPS AND DAMPENERS | HERRMANN, JOSEPH S | 3746 | §103 | Final Rejection | 75d | Pending | Mar 07, 2023 |
| 18071705 | RNA FORMULATION FOR IMMUNOTHERAPY | SHOMER, ISAAC | 1612 | Other | Final Rejection | 80d overdue | Pending | Nov 30, 2022 |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 3736 | §103 | Final Rejection | 55d | Pending | Oct 21, 2022 |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 1674 | §103 | Non-Final OA | 67d overdue | Pending | Sep 29, 2022 |
| 17913743 | RNA PARTICLES COMPRISING POLYSARCOSINE | POPA, ILEANA | 1633 | §103 | Non-Final OA | 60d overdue | Pending | Sep 22, 2022 |
| 17289602 | FORMULATIONS OF MULTISPECIFIC ANTIBODIES BINDING PD-L1 AND CD137 | KIM, YUNSOO | 1641 | Other | Non-Final OA | 49d overdue | Pending | Apr 28, 2021 |
| 16318895 | Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy | GODDARD, LAURA B | 1642 | §103 | Final Rejection | 19d | Pending | Jan 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial